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Available online 14 May 2016Background: Natriuretic peptides play an important role in the diagnosis and risk stratiﬁcation of patients with
acute and chronic heart failure. Multiple studies have shown that these peptides are liable to the inﬂuence of
individual factors. For N-terminal-pro-B-type natriuretic peptide (NT-proBNP) some of these confounding
factors have been evaluated over the years such as age, gender, New York Heart Association (NYHA) class and
body mass index (BMI). The aim of this study was to establish confounding factors of mid-regional pro-atrial
natriuretic peptide (MR-proANP) assessment.
Methods and results: We studied 684 patients (94% male, age 61.2 ± 11.2, left ventricular ejection fraction
[LVEF] b 35%–45%, NYHA class (I/II/III/IV: 8.4/45.8/39.5/6.3%), ischaemic aetiology 71%, body mass index [BMI]
26.5 ± 4.3 kg/m2, mean MR-proANP 296.0 ± 281.0 pmol/L, mean NT-proBNP 2792.0 ± 5328.6 pg/mL, mean
creatinine level 110.2 ± 38.0 μmol/L and mean haemoglobin 13.9 ± 1.5 g/dL) with clinically stable chronic
heart failure. MR-proANP levels increased with increasing NYHA class (p b 0.0001) and an increasing BMI
category was associated with decreasing values of MR-proANP (p b 0.0001). We found MR-proANP to be
independently associated with BMI, creatinine, ischaemic aetiology, LVEF and NYHA class. Meanwhile, NT-
proBNP was independently associated with BMI, creatinine, haemoglobin, LVEF and NYHA class.
Conclusion: MR-proANP is subject to the almost identical inﬂuencing factors like NT-proBNP. The effects of
anaemia warrant further study.
© 2016 Published by Elsevier Ireland Ltd.Keywords:
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Biomarker1. Introduction
Heart failure (HF) is a common syndrome in industrialised coun-
tries around the world. Currently, an estimated 5.8 million people in
the United States [1] and roughly 1–2% of the adult population in de-
veloped countries [2] are living with HF. Recent projections in the
United States show an estimated increase in the prevalence of HF
by 23%, which means that by 2030 N 8 million people in the United
States will live with HF [3]. HF is a condition with poor long-termtriuretic peptide; HF, heart fail-
s index; NT-proBNP, N-terminal
sociation.
Clinical Trials, Department of
Medical School, Robert-Koch-
Haehling).prognosis and therefore it is important to diagnose and treat the
syndrome as early as possible. To date, a deﬁnitive diagnosis of HF
based on symptoms and physical exam ﬁndings is often not sensitive
enough to reach an accurate diagnosis [4]. Known as the gold stan-
dard, echocardiography is time-consuming, comparatively expen-
sive, not available everywhere and may not always reﬂect an acute
condition [4]. Over the last decades, natriuretic peptides, which are
being secreted from the atria and the ventricles as a consequence
of increased tension due to volume expansion [5], have been
established as having an important role in the diagnostic and prog-
nostic assessment of patients with HF. The two most recognised na-
triuretic peptides are atrial natriuretic peptide (ANP) and B-type
natriuretic peptide (BNP) with their readily assessable andmore sta-
ble precursors pro-ANP and pro-BNP. The ﬁrst assays for mature BNP
became available in 1993 [6], the ﬁrst for its N-terminal precursor N-
terminal-proBNP (NT-proBNP) in late 2002 [6]. Over the years,
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measuring BNP and NT-proBNP [7,8]. Today, the measurement of
the natriuretic peptides BNP and NT-proBNP carries a class IIA
recommendation in the HF guidelines of the European Society of
Cardiology (ESC) and a class I recommendation in the joint HF guide-
lines of the American College of Cardiology Foundation and the
American Heart Association (ACCF/AHA) [2,9]. Since the develop-
ment of an immunoassay able to detect the mid-regional sequence
of NT-pro-ANP [10], commercially available since early 2004 [10],
the novel marker MR-proANP has received increasing attention as a
cardiac marker, and a large number of studies have investigated its
clinical utilities. Different studies veriﬁed MR-proANP to be non-
inferior to BNP and NT-proBNP with regards to diagnostic and
prognostic questions in HF patients' assessment [11,12,13]. In partic-
ular, the non-inferiority of MR-proANP in the diagnosis of acute HF
among patients presenting with acute dyspnoea to the emergency
department has been established [14].
Previous studies conﬁrmed BNP and NT-proBNP to be prone to
inﬂuences of confounding factors such as age, gender, race, or body
mass index (BMI) [7]. With advancing age, serum levels of BNP and
NT-proBNP rise and with increasing BMI the levels of both NPs de-
crease. Knowledge of such factors may be important, as they may
have signiﬁcant effects on test results and on the management of a
given patient. A thorough evaluation of confounding factors of MR-
proANP has not been performed to date. Using data from a large
cohort of patients, we aimed to establish clinically signiﬁcant
confounders of MR-proANP serum values in patients with chronic
HF and to compare our ﬁndings with confounding factors of NT-
proBNP assessment.2. Methods
2.1. Study population
Patients for this analysis were recruited as part of a previous
biomarker project by von Haehling et al. [13]. This approach yielded a
patient population of 684 patients with stable chronic HF, recruited at
5 European centres in Athens (Greece, n = 33), London (UK, n = 84),
Verona (Italy, n = 196), Wroclaw (Poland, n = 242) and Zabrze
(Poland, n = 129) (Fig. 1). All participants were recruited for a studyFig. 1. Flowchart of thedesigned to investigate prognostic biomarkers [13] and had signed
written informed consent in this regard. The study protocol was ap-
proved by the local ethics committees. To be included, participants
had to have a history of chronic HF of at least 3 month duration with a
left ventricular ejection fraction (LVEF) ≤45%. Medication was not to
be changed 4 weeks prior to enrolment.
2.2. Biochemical and statistical analysis
MR-proANP and NT-proBNP were assessed from serum or plasma
samples frozen at −80 °C until analysis. MR-proANP values were
analysed using an automated sandwich chemiluminescence immuno-
assay on the KRYPTOR System (Thermo Fisher/B.R.A.H.M.S. GmbH,
Henningsdorf, Germany) with a within-run imprecision coefﬁcient of
variation of 1.2% and a total imprecision of 5.4% and a lower limit of
quantiﬁcation of 4.5 pmol/L as described previously [14]. The median
value of MR-proANP in healthy blood donors was 45 pmol/L with a
range of 9.6–313 pmol/L [10]. An electrochemiluminescence
immunoassay (ELICIA, Roche Diagnostics, Basel, Switzerland) was
used for the determination of NT-proBNP values. The values for serum
creatinine and haemoglobin were obtained by standard laboratory
techniques.
To deﬁne anaemia we used the World Health Organisation criteria
with haemoglobin b12 g/dl in women and haemoglobin b13 g/dl in
men [15].
2.3. Statistical analysis
All data are shown as mean ± standard deviation (SD) and as
median with upper and lower quartiles. All data were checked for
normal distribution prior to analysis using the Kolmogorov–Smirnov-
test. Non-normally distributed data (MR-proANP, NT-proBNP, and
creatinine) were log-transformed before analysis to achieve a normal
distribution. We used Student's t-test and analysis of variance
(ANOVA) to compare differences and simple regression and multivari-
ate stepwise regression using backward selection to identify factors,
which are independently associated with MR-proANP and NT-proBNP.
A value of p b 0.05 was considered to be signiﬁcant. All analyses were
performed using StatView version 5.0 software for Windows (Abacus
Concepts, Berkeley, California).study population.
Table 2
Patient's characteristics — part 2.
n = 684
Patients with anaemia (%) 24
Haemoglobin [g/dL] 13.9 ± 1.5
Sodium [mmol/L] 139.2 ± 4.4
Potassium [mmol/L] 4.4 ± 0.5
Creatinine [μmol/L] 110.2 ± 38.0
White blood cells [×1000/μL] 7.1 ± 2.1
Platelets [×1000/μL] 206.7 ± 62.1
Uric acid [μmol/L] 427.4 ± 145.6
MR-proANP [pmol/L] 296.0 ± 281.0
NT-proBNP [pg/mL] 2792.0 ± 5328.6
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3.1. Main cohort
Patients in the cohort (n=684)werepredominantlymale (94%)with
a mean age of 61.2 ± 11.2 years and a mean BMI of 26.5 ± 4.3 kg/m2.
Anaemia was detected in 161 (24%) patients: 13 women and 148 men.
Serum levels of MR-proANP ranged from 24.5–2280.0 pmol/L with a
mean of 296.0 ± 281.0 pmol/L and a median of 210.0 pmol/L (25th
percentile 122.0 pmol/L, 75th percentile 383.0 pmol/L). The correspond-
ing values for NT-proBNP ranged from 20.0–88,300.0 pg/mL with a
mean of 2792.0 ± 5328.6 pg/mL and a median of 1109.5 pg/mL (25th
percentile 451.1 pg/mL, 75th percentile 3085.0 pg/mL).
Patients taking aspirin (p b 0.0001), diuretics (p = 0.0003),
spironolactone (p b 0.0001), statins (p = 0.002), digoxin (p b 0.0001)
or warfarin (p = 0.004) had higher MR-proANP levels than patients
not on any of these medications. Serum levels of NT-proBNP were
higher in patients taking aspirin (p = 0.0001), diuretics (p = 0.03),
spironolactone (p = 0.0005), statins (p b 0.0001), digoxin (p =
0.0008), or angiotensin converting enzyme inhibitors/angiotensin-
receptor-blockers (ACE or ARB) (p = 0.004) than in patients without
these medications. Patients' characteristics and medication are shown
(Tables 1 and 2).
Using simple regression we found that MR-proANP correlated with
age (r = 0.16, p b 0.0001), BMI (r =−0.23, p b 0.0001), serum creati-
nine (r = 0.40, p b 0.0001), and LVEF (r = 0.31, p b 0.0001). Further-
more, we were able to show that ischaemic aetiology (r = 0.104, p =
0.006), haemoglobin (r = −0.191, p b 0.0001) and NYHA class (r =
0.444, p b 0.0001)were also associatedwithMR-proANP but not gender
(r = 0.005, p = 0.90) (Fig. 2). Multivariate stepwise regression using
backward selection showedMR-proANP to be independently associated
with BMI (sc = −0.17, p b 0.0001), serum creatinine (sc = 0.29,
p b 0.0001), aetiology (sc = 0.08, p = 0.02), LVEF (sc = 0.21,
p b 0.0001), and NYHA class (sc = 0.29, p b 0.0001), but not with age
(sc=0.05, p=0.13), haemoglobin (sc=−0.01, p=0.67), and gender
(sc = 0.01, p = 0.75). Details can be found in (Table 3).
Simple linear regression showed serumNT-proBNP to correlatewith
BMI (r =−0.24, p b 0.0001), serum creatinine (r = 0.30, p b 0.0001),
haemoglobin (r = −0.24, p b 0.0001), LVEF (r = 0.32, p b 0.0001),
and NYHA class (r = 0.40, p b 0.0001). Our study did not show an
independent association of logNT-proBNP and age (r = 0.05, p =
0.16), ischaemic aetiology (r = 0.05, p = 0.16) or gender (r =−0.01,
p = 0.80) (Fig. 3). Using multivariate stepwise regression with
backwards selection we found NT-proBNP to be independently
associated with BMI (sc = −0.17, p b 0.0001), serum creatinine
(sc = 0.19, p b 0.0001), haemoglobin (sc =−0.10, p = 0.0003), LVEF
(sc = 0.21, p b 0.0001), and NYHA class (sc = 0.26, p b 0.0001), but
not with age (sc = −0.03, p = 0.38), gender (sc = 0.02, p = 0.54)Table 1
Patient's characteristics — part 1.
n = 684
Age (years) 61.2 ± 11.2
Male gender (%) 94
Weight (kg) 78.8 ± 14.4
BMI (kg/m2) 26.5 ± 4.3
Cause of heart failure (% ischaemic) 71
NYHA functional class (I/II/III/IV) 58/313/270/43
Left ventricular ejection fraction (%) 30.0 ± 8.0
Left ventricular ejection fraction (%)
(Category 1: b35%/2: 35–44%)
65/35
ACE inhibitor or ARB (%) 92
Beta-blockers (%) 73
Aspirin (%) 57
Any diuretic other than spironolactone (%) 75
Spironolactone (%) 36
Warfarin (%) 25and aetiology (sc = 0.006, p = 0.11). Details can be found in
(Table 3). No material change was noted in the results when women
were excluded from the analysis.
We not only found an inverse relationship between haemoglobin
values and biomarkers, closer analysis of anaemia revealed a signiﬁcant
correlation between haemoglobin and gender (p b 0.0001). Women
with anaemia had signiﬁcantly higher MR-proANP (p = 0.0097) and
NT-proBNP (p = 0.0025) values than women without anaemia. We
found the same to be true for men (all p b 0.0001, Table 4).
4. Discussion
Our study systematically evaluated confounding factors of MR-
proANP assessment. Our data show that the main inﬂuencing factors
of MR-proANP serum levels are NYHA class, serum creatinine, LVEF,
and BMI with descending importance. Aetiology of HF also remained a
weak, but independently associated confounder of MR-proANP. Apart
from disease aetiology, these results are similar to our ﬁndings for NT-
proBNP, whose most important inﬂuencing factors are NYHA class,
LVEF, serum creatinine, and BMI with descending signiﬁcance. In
addition, haemoglobin remained independently predictive of NT-
proBNP levels. Even though a trend towards signiﬁcance existed, age
was not independently predictive of either MR-proANP or NT-proBNP
in this cohort of patients. Gender does not inﬂuence either of the two
markers. A thorough understanding of such confounding factors is
important for the interpretation of MR-proANP results in clinical
practise. Indeed, MR-proANP has recently received wider attention,
since recent studies have shown its non-inferiority compared to BNP
for making a correct diagnosis of acute HF in the emergency setting
(Maisel, JACC 2010, BACH) [14]. Some studies have also highlighted
better prognostic value compared to BNP and NT-proBNP [11,16,17,18,
19].
A recent study of 1352 patients, who came to the emergency room
with acute dyspnoea, found MR-proANP levels to increase with age,
were higher in men with the ﬁnal diagnose of HF than women and
decreased with increasing BMI. Additionally, they showed that the
diagnostic accuracy of MR-proANP was inﬂuenced by race and age but
not gender or BMI [20]. Indeed, MR-proANP levels increase with
NYHA class, reduced kidney function, are higher in patients with a low
LVEF and decrease with BMI and rising values of haemoglobin.
For BNP and NT-proBNP, similar results had been published before.
In fact, the above described inverse relationship between BMI and
MR-proANP as well as NT-proBNP were reported already in previous
studies [20,21,22,23,24,25]. Different hypotheses have been proposed
to explain this ﬁnding. Sarzani et al. postulated that an increased
expression of natriuretic peptide clearance receptors (NPR-C) in
adipose tissue might be responsible for lower levels of BNP in obese
patients due to an increased clearance of natriuretic peptides from the
circulation [26]. However, since MR-proANP and NT-proANP are
structurally different from BNP, it is unlikely that they are cleared
through natriuretic peptide clearance receptors only. In addition,
clearance mechanisms of the two natriuretic peptides are presumed to
Fig. 2. Relationship between logMR-proANP and age (a), MR-proANP and gender (b), MR-proANP and haemoglobin (c), MR-proANP and anaemia (d), MR-proANP and LVEF (e) andMR-
proANP and BMI by categories (f).
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decreased secretion or blunted up-regulation of natriuretic peptides
are the reason for their lowered levels in obese patients, a reduced
clearance appears to play only a secondary role [20,21,24,25,27,28].
Previous studies had observed a signiﬁcant inﬂuence of advancing
age on natriuretic peptide levels in healthy subjects as well as in
patients with chronic HF [12,13,22,29,30]. In line with these previousﬁndings, we also found MR-proANP to rise with age. Nevertheless, this
effect was attenuated after multivariable adjustment for BMI, gender,
kidney function, aetiology, and LVEF, with only a trend towards
signiﬁcance remaining. Similar effects were observed for NT-proBNP.
Indeed, not all previous studies have established an effect of ageing on
natriuretic peptide levels. Schou et al. [31] analysed the data of 345
patients with chronic HF. They found age to be signiﬁcantly associated
Table 3
Univariable and multivariable regression for MR-proANP and NT-proBNP.
Mode Univariable regression Multivariable regression
Dependent logMR-proANP logNT-proBNP logMR-proANP logNT-proBNP
Age (years) r = 0.157,
p b 0.0001
r = 0.054,
p = 0.16
sc = 0.05,
p = 0.13
sc =− 0.031,
p = 0.38
Sex r = 0.005,
p = 0.90
r =−0.010,
p = 0.80
sc = 0.010,
p = 0.75
sc = 0.021,
p = 0.54
BMI (kg/m2) r =−0.232,
p b 0.0001
r =−0.240,
p b 0.0001
sc =−0.173,
p b 0.0001
sc =−0.171,
p b 0.0001
Aetiology (ischaemic) r = 0.104,
p = 0.0062
r = 0.054,
p = 0.16
sc = 0.076,
p = 0.0185
sc = 0.055,
p = 0.11
NYHA Class (I/II/III/IV) r = 0.444,
p b 0.0001
r = 0.403,
p b 0.0001
sc = 0.291,
p b 0.0001
sc = 0.261,
p b 0.0001
LV-Function (1-best LVEF) r = 0.311,
p b 0.0001
r = 0.322,
p b 0.0001
sc = 0.210,
p b 0.0001
sc = 0.218,
p b 0.0001
logCreatinine (μmol/L) r = 0.398,
p b 0.0001
r = 0.297,
p b 0.0001
sc = 0.285,
p b 0.0001
sc = 0.193,
p b 0.0001
Haemoglobin (g/dL) r =−0.191,
p b 0.0001
r =−0.241,
p b 0.0001
sc =−0.014
p = 0.67
sc =−0.102,
p = 0.0032
All values with logANP and logBNP and logCreat.
Bold numbers indicate signiﬁcance at p b 0.05.
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Moertl et al. measuredMR-proANP, BNP andNT-proBNP in 797 patients
with chronic HF. In their multiple linear regression analysis they
showed LVEF, glomerularﬁltration rate (GFR) and ankle edema to be in-
dependent predictors of all the natriuretic peptides but age and BMI
were not [11]. Their ﬁndings are thus in accordance with our data, and
we agree with their statement that age and sex may not be relevant in
patients with HF in whom factors such as ventricular function, volume
status, and renal function become more relevant [11].
Natriuretic peptides are secreted from cardiomyocytes in response
to excessive cardiacwall stretch and induce vasodilatation and natriure-
sis. By doing so, natriuretic peptides aid in lowering blood pressure and
cardiac afterload and help to increase the cardiac output at the same
time. Therefore, it is not uncommon that patients with higher NYHA
class have higher biomarker values due to the advanced stress on the
heart. In our study, a trend was found between MR-proANP, NT-
proBNP and NYHA class which has also been shown by Masson et al.
[22]. With increasing NYHA class the values of MR-proANP and NT-
proBNP increased accordingly. However, signiﬁcance was not observed
for all NYHA stages. This was mainly because the patient distribution
was not balanced in all individual NYHA stages. A similar mechanism
can be used to explain the association between LVEF and natriuretic
peptides. In patients with impaired LVEF, the left ventricle does not
empty sufﬁciently. This leads to ventricular volume overload and an el-
evated end-diastolic pressure. This brings about stretching of the left
ventricular wall and an associated release of cardiac biomarkers. With
increasing restriction of LVEF, the volume fraction of non-ejected
blood volume increases, which in turn is reﬂected in an increased
stretching of the cardiac walls and increased secretion of natriuretic
peptides [32]. We found a signiﬁcant inverse relationship between
MR-proANP, NT-proBNP and LVEF, a result with has previously also
been reported by Elmas et al. [33] in 102 patients with coronary artery
disease and Eggers et al. [34] in 999 community-dwelling subjects
aged 70 years participating in the Prospective Investigation of the
Vasculature in Uppsala Seniors (PIVUS) study.
In the present study, a signiﬁcant correlation between serum
creatinine andMR-proANP aswell asNT-proBNPwas observed. Patients
with increasing creatinine values had signiﬁcantly higher values of MR-
proANP and NT-proBNP. This ﬁnding is in agreement with several
previous studies [11,22,35,36,37]. When looking at haemoglobin, we
were able to show that haemoglobin may have an inﬂuence on NT-
proBNP levels in a multivariable setting, but not MR-proANP. In our
study, anaemic had signiﬁcantly higher MR-proANP and NT-proBNP
values than patients with normal haemoglobin values, which may also
be viewed as more advanced HF. In multivariable regression, theassociation betweenhaemoglobin andNT-proBNP remained signiﬁcant,
while MR-proANP became insigniﬁcant. When looking just at anaemia,
we found MR-proANP and NT-proBNP levels to be slightly higher in
anaemic women than in anaemic men. This might be caused by the
different cut-off points used to deﬁne anaemia for men and women.
An association between NT-proBNP and haemoglobin was also found
by Desai et al. in their analysis of 189 anaemic patients with coronary
heart disease form the Heart and Soul Study [38]. Here lower
haemoglobin values were linearly associated with higher mean levels
of log NT-proBNP. Hogenhuis et al. also found a signiﬁcant negative
association between both BNP andNT-proBNP andhaemoglobin in a co-
hort of 541 patients hospitalised for HF [30] and a study on 137 diastolic
HF patients equally showed a signiﬁcant inverse relationship between
BNP and haemoglobin (p b 0.0001) [39]. Anaemia is repeatedly seen
in patients with HF. Estimates of the incidence of anaemia in patients
with HF vary considerably from 4 up to 61% and are related to clinical
characteristics of the studied population [40]. The reason of anaemia
in patients with HF could be caused by renal damage due to restricted
cardiac function [41] or iron deﬁciency evoked by decreased intestinal
iron uptake caused by elevated pro-inﬂammatory cytokines blocking
the absorption [40].
HF is a common disease with an excepted rise in prevalence over
the next decades. It still is a disease with a limited life expectancy,
thus early diagnosis and treatment is essential. The diagnosis based
on physical examination and symptoms can be vague and echocardi-
ography might not be available everywhere at any time. Therefore,
the determination of natriuretic peptides for diagnostic and risk
stratiﬁcation purposes in patients with acute and chronic HF has
gained increasing importance in recent years and is now mentioned
in the guidelines for HF [2,9]. BNP and NT-proBNP are already well-
established cardiac biomarkers. MR-proANP gained more recogni-
tion after introduction of a new measurement method a few years
back. Natriuretic peptides are released from cardiomyocytes due to
increased wall stretching and are subject to inﬂuencing factors.
Those have been investigated for BNP and NT-proBNP in various
studies. For MR-proANP there has been little information. Our
study was designed to investigate the confounding factors of MR-
proANP in comparison with the ﬁndings for NT-proBNP. We found
that MR-proANP and NT-proBNP share many inﬂuencing factors.
MR-proANP values increase with rising NYHA class, decreasing
renal function, are higher in patients with reduced LVEF and
decrease with increasing BMI and haemoglobin values. The results
for NT-proBNPwere similar, additionally it also showed a correlation
between NT-proBNP and haemoglobin. Age and gender did not have
an effect on the natriuretic peptide values in our cohort.
Fig. 3. Relationship between logNT-proBNP and age (a), NT-proBNP and gender (b), NT-proBNP and haemoglobin (c), NT-proBNP and anaemia (d), NT-proBNP and LVEF (e) and NT-
proBNP and BMI by categories (f).
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In conclusion, MR-proANP is subject to the same inﬂuencing factors
as NT-proBNP, except for haemoglobin, which only remained indepen-
dently associated with NT-proBNP. Anaemia is frequently seen inpatients with HF, therefore further studies will be needed to determine
whether NT-proBNP needs to be adjusted for anaemia before
interpreting results. Since MR-proANP seems not to be inﬂuenced by
haemoglobin values, it might be more reliable in the diagnosis of HF in
anaemic patients.
Table 4
Biomarker values and anaemia.
Gender Female (n = 42) Male (n = 642)
Anaemia Anaemia
Yes (n = 13) No (n = 29) p value Yes (n = 148) No (n = 494) p value
MR-proANP [pmol/L] 510.5 ± 574.4 208.3 ± 131.0 0.0097 413.0 ± 350.0 260.4 ± 239.0 b0.0001
NT-proBNP [pg/mL] 5108.0 ± 5621.0 1517.0 ± 1522.3 0.0025 4551.8 ± 6084.0 2278.7 ± 5096.0 b0.0001
Bold numbers indicate signiﬁcance at p b 0.05.
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